Traumatology

ArthroVisc®40 is a non-cross-linked hyaluronic acid (2 %) obtained from bacterial fermentation. This product is sterile and non-pyrogenic. It is packaged in 2 ml syringes of hyaluronic acid ( 20 mg/ml, 1500 KDa). ArthroVisc®40 is available in three syringes of 2 ml. It is for single use and designed to be used with sterile needles (25G or 27G), not supplied in the kit. Composition : 2 mL of solution contains 40mg of hyaluronic acid in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride) and water for injection.

Cellular Matrix® tubes allow the preparation of autologous platelet-rich plasma (RegenPRP®) combined with non-cross-linked hyaluronic acid (HA) in a closed-loop system. CM-PRP-HA has an excellent safety profile in clinical practice. Cellular Matrix® technology combines the complementary clinical effects of RegenPRP® and hyaluronic acid (HA), providing better, longer-lasting results in patients with osteoarthritis. Hyaluronic acid

• Hyaluronic acid is an important component of synovial fluid that contributes to joint homeostasis.
• 25 years of clinical experience shows pain relief and functional improvement lasting 6 to 12 months in patients with OA.
• It plays an important role in viscosupplementation and pain relief in OA.
• The network of HA chains generates an ideal matrix for cells when combined with PRP.
• Hyaluronic acid enhances the activity of several molecules contained in platelet-rich plasma to provide additional benefits to OA patients.